Literature DB >> 19783325

Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility.

Federico Perez1, Andrea M Hujer, Edward A Hulten, Joel Fishbain, Kristine M Hujer, David Aron, Katherine Thweatt, Curtis J Donskey, Robert A Bonomo.   

Abstract

We explored the association of antibiotic-resistant phenotypes and genotypes in Acinetobacter spp with clinical outcomes and characteristics in 75 patients from a major military treatment facility. Amikacin resistance was associated with nosocomial acquisition of A baumannii, and carbapenem resistance and bla(OXA-23) were associated with the need for mechanical ventilation. The presence of bla(OXA-23) also correlated with longer hospital and ICU stay. Associations between bla(OXA-23) and complexity, duration, and changes made to antibiotic regimens also existed. Copyright 2010. Published by Mosby, Inc.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19783325      PMCID： PMC4085753          DOI： 10.1016/j.ajic.2009.05.007

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN： 0196-6553            Impact factor:   2.918


  9 in total

1.  An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq.

Authors:  Paul Scott; Gregory Deye; Arjun Srinivasan; Clinton Murray; Kimberly Moran; Ed Hulten; Joel Fishbain; David Craft; Scott Riddell; Luther Lindler; James Mancuso; Eric Milstrey; Christian T Bautista; Jean Patel; Alessa Ewell; Tacita Hamilton; Charla Gaddy; Martin Tenney; George Christopher; Kyle Petersen; Timothy Endy; Bruno Petruccelli
Journal:  Clin Infect Dis       Date:  2007-05-08       Impact factor: 9.079

Review 2.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 3.  Acinetobacter infection.

Authors:  L Silvia Munoz-Price; Robert A Weinstein
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

4.  Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia.

Authors:  Ki Tae Kwon; Won Sup Oh; Jae-Hoon Song; Hyun-Ha Chang; Sook-In Jung; Shin-Woo Kim; Seong Yeol Ryu; Sang Taek Heo; Dong Sik Jung; Ji-Young Rhee; Sang Yop Shin; Kwan Soo Ko; Kyong Ran Peck; Nam Yong Lee
Journal:  J Antimicrob Chemother       Date:  2007-01-09       Impact factor: 5.790

5.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

6.  Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.

Authors:  Rebecca H Sunenshine; Marc-Oliver Wright; Lisa L Maragakis; Anthony D Harris; Xiaoyan Song; Joan Hebden; Sara E Cosgrove; Ashley Anderson; Jennifer Carnell; Daniel B Jernigan; David G Kleinbaum; Trish M Perl; Harold C Standiford; Arjun Srinivasan
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.

Authors:  Lisa L Maragakis; Trish M Perl
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

9.  Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.

Authors:  Nan-Yao Lee; Hsin-Chun Lee; Nai-Ying Ko; Chia-Ming Chang; Hsin-I Shih; Chi-Jung Wu; Wen-Chien Ko
Journal:  Infect Control Hosp Epidemiol       Date:  2007-05-14       Impact factor: 3.254
  9 in total
  13 in total

1.  Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient.

Authors:  G Patel; F Perez; A M Hujer; S D Rudin; J J Augustine; G H Jacobs; M R Jacobs; R A Bonomo
Journal:  Transpl Infect Dis       Date:  2015-02-06       Impact factor: 2.228

2.  Acinetobacter baumannii isolates from pets and horses in Switzerland: molecular characterization and clinical data.

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Isabelle Bertschy; Alexandra Rossano; Christoph Koch; Vinzenz Gerber; Thierry Francey; Robert A Bonomo; Vincent Perreten
Journal:  J Antimicrob Chemother       Date:  2011-07-06       Impact factor: 5.790

3.  Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.

Authors:  Sherief El-Shazly; Ali Dashti; Leila Vali; Michael Bolaris; Ashraf S Ibrahim
Journal:  Int J Infect Dis       Date:  2015-10-27       Impact factor: 3.623

4.  Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III.

Authors:  Scott R Evans; Andrea M Hujer; Hongyu Jiang; Carol B Hill; Kristine M Hujer; Jose R Mediavilla; Claudia Manca; Thuy Tien T Tran; T Nicholas Domitrovic; Paul G Higgins; Harald Seifert; Barry N Kreiswirth; Robin Patel; Michael R Jacobs; Liang Chen; Rangarajan Sampath; Thomas Hall; Christine Marzan; Vance G Fowler; Henry F Chambers; Robert A Bonomo
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

5.  Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center.

Authors:  Kyle Petersen; Suzanne C Cannegieter; Tanny J van der Reijden; Beppie van Strijen; David M You; Britta S Babel; Andrew I Philip; Lenie Dijkshoorn
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

6.  Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination.

Authors:  Federico Perez; Andrea Endimiani; Amy J Ray; Brooke K Decker; Christopher J Wallace; Kristine M Hujer; David J Ecker; Mark D Adams; Philip Toltzis; Michael J Dul; Anne Windau; Saralee Bajaksouzian; Michael R Jacobs; Robert A Salata; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2010-05-31       Impact factor: 5.790

7.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

8.  Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities.

Authors:  Chris Rowe Taitt; Tomasz A Leski; Michael G Stockelman; David W Craft; Daniel V Zurawski; Benjamin C Kirkup; Gary J Vora
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

9.  Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Beverlie Baquir; Andrew Tomaras; Justin I Montgomery; Usa Reilly; Elsa G Barbacci; Kristine Hujer; Robert A Bonomo; Lucia Fernandez; Robert E W Hancock; Mark D Adams; Samuel W French; Virgil S Buslon; Brad Spellberg
Journal:  MBio       Date:  2012-10-02       Impact factor: 7.867

10.  "Stormy waters ahead": global emergence of carbapenemases.

Authors:  Gopi Patel; Robert A Bonomo
Journal:  Front Microbiol       Date:  2013-03-14       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.